LY4065967

Phase 2

Eli Lilly and Company (LLY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

LLYPhase 2$1.1T

LY4065967 Phase 2 Est. Readout

LY4065967• Diabetic Peripheral Neuropathic Pain150

Jul 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Diabetic Peripheral Neuropathic Pain

View Full Landscape

Drug Information

Target Indication

Diabetic Peripheral Neuropathic Pain

Clinical Trial

NCT07285018

Last updated: 2/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

somatropin, rDNA origin, for injectionPhase 3

Growth Disorder

Ultra-Rapid LisproPhase 3

Type 1 Diabetes Mellitus

RetatrutidePhase 3

Obesity

Atomoxetine HydrochloridePhase 3

Attention Deficit Hyperactivity Disorder

LY2216684Phase 3

Major Depressive Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts